Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NAMPT | P43490 | 3/20 | 0.48 |
| ▸ | PIK3CA | P42336 | 4/20 | 0.44 |
| ▸ | MTOR | P42345 | 4/20 | 0.44 |
| ▸ | EPHX2 | P34913 | 6/20 | 0.43 |
| ▸ | AURKA | O14965 | 1/20 | 0.42 |
| ▸ | RPS6KB1 | P23443 | 1/20 | 0.42 |
| ▸ | CNR1 | P21554 | 1/20 | 0.41 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.41 |
| ▸ | LMNA | P02545 | 1/20 | 0.41 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.41 |
| ▸ | HPGD | P15428 | 2/20 | 0.41 |
| ▸ | NPC1 | O15118 | 1/20 | 0.41 |
| ▸ | POLB | P06746 | 1/20 | 0.41 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3046413 | 0.93 | NAMPT (0.46) | NAMPTEPHX2CNR1 | |
| SCHEMBL3054387 | 0.93 | NAMPT (0.47) | NAMPTEPHX2 | |
| SCHEMBL3050002 | 0.93 | NAMPT (0.47) | NAMPTEPHX2 | |
| SCHEMBL3054878 | 0.92 | NAMPT (0.41) | NAMPTPIK3CAMTOREPHX2 | |
| SCHEMBL3047217 | 0.91 | NAMPT (0.41) | NAMPTPIK3CAMTOR | |
| SCHEMBL3051319 | 0.91 | NAMPT (0.40) | NAMPTPIK3CAMTOR | |
| SCHEMBL3055649 | 0.89 | NAMPT (0.41) | NAMPTMTOR | |
| SCHEMBL3061361 | 0.88 | NAMPT (0.40) | NAMPTPIK3CAMTOR | |
| SCHEMBL3054524 | 0.86 | HDAC1 (0.46) | NAMPTPOLB | |
| SCHEMBL3051338 | 0.85 | NAMPT (0.48) | NAMPTEPHX2POLB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100222319-A1 | NICOTINAMIDE DERIVATIVES, PREPARATION THEREOF AND THERAPEUTIC USE THEREOF | SANOFI-AVENTIS (FR) | 2010-09-02 | — | — | US | claimed |
| US-20100222319-A1 | NICOTINAMIDE DERIVATIVES, PREPARATION THEREOF AND THERAPEUTIC USE THEREOF | SANOFI-AVENTIS (FR) | 2010-09-02 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100222319-A1 | NICOTINAMIDE DERIVATIVES, PREPARATION THEREOF AND THERAPEUTIC USE THEREOF | NNT, NAMPT, NQO1 | NAMPT 2/4885PIK3CA 1063/4885MTOR 2266/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.